Optimizing individual treatment outcomes in men with lower urinary tract symptoms using storage subscale score/total International Prostate Symptom Score (IPSS) as a new IPSS lratio by Altintaş, S. et al.
1124
http://journals.tubitak.gov.tr/medical/




Optimizing individual treatment outcomes in men with lower urinary
tract symptoms using storage subscale score/total International
Prostate Symptom Score (IPSS) as a new IPSS ratio
Serkan ALTINTAŞ, İsmail Cenk ACAR*, Saadettin Yılmaz ESKİÇORAPÇI, Ali Ersin ZÜMRÜTBAŞ,
Deniz BOLAT, Ömer Levent TUNCAY, Mehmet Zafer SINIK
Department Of Urology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
* Correspondence: acarcenk@hotmail.com
1. Introduction
Lower urinary tract symptoms (LUTS) indicate the 
pathologies of storage, voiding, and the postmicturition 
phases of urination (1). The results of a large prevalence study 
showed that storage symptoms such as urine frequency, 
nocturia, urgency, and urge incontinence were more 
prevalent (51.3%) than other LUTS in men (2). In recent 
years, the paradigm shifted from the prostate to the bladder 
for understanding, diagnosis, and treatment strategies of 
LUTS in men. Accordingly, detrusor overactivity (DO) 
and bladder outlet obstruction (BOO) play integral roles in 
men with LUTS (3). Overactive bladder (OAB) symptoms 
have more deteriorating effects on health-related quality 
of life (QoL) than other LUTS (4,5). Furthermore, recent 
studies have emphasized that combination therapy 
(ComRx) with α-blockers and antimuscarinics had better 
results in men with BOO who had mixed symptoms (6). In 
contrast, LUTS in men are often still treated with therapies 
targeting the prostate even if they have OAB symptoms (1). 
Although DO and OAB symptoms may develop secondary 
to BOO in men, they also may occur independently (7,8). 
Determination of the dominating pathology in the clinical 
scenario of patients with LUTS is a major concern in opting 
for medical therapy. 
The International Prostate Symptom Score (IPSS) is 
the most relevant tool to assess the severity of LUTS (9). 
Three of the 7 questions evaluate storage symptoms and 
1 evaluates QoL. The major disadvantage of the IPSS total 
score is its inability to determine potential etiologies. 
Urodynamic evaluation is the gold standard but it is an 
invasive method. There is no widely accepted noninvasive 
diagnostic test to identify dominant symptoms of storage 
or voiding in LUTS. Recently, the importance of the 
IPSS has become well recognized and some authors have 
published data that constitute different IPSS ratios (10,11). 
The objective of the present study was to evaluate the 
effect of the storage/total IPSS ratio (s/T) as a new tool to 
individualize medical therapy in men with LUTS.
Background/aim: To evaluate the effects of the storage/total International Prostate Symptom Score (s/T) ratio on the selection and 
success of medical therapy in men with lower urinary tract symptoms (LUTS).
Materials and methods: A total of 54 men (>45 years of age) with moderate or severe LUTS were divided into 2 groups according 
to the s/T ratio: Group 1 at <0.43 and Group 2 at >0.43. Tamsulosin (0.4 mg to Group 1) and tolterodine ER (4 mg to Group 2) were 
administered. Patients were evaluated during the 1st and 3rd months of follow-up treatment.
Results: Thirty-seven (68.5%) and 17 (31.5%) patients were in Groups 1 and 2, respectively. The mean s/T ratios in Groups 1 and 2 
increased to 0.38 ± 0.19 from 0.33 ± 0.08 (P = 0.03) and decreased to 0.54 ± 0.18 from 0.59 ± 0.1 (P = 0.17) during the 3rd month of 
follow-up, respectively. The treatment success rates of Groups 1 and 2 were 88.4% and 75.7%, respectively. Nine unsuccessful cases were 
treated with combination therapy and the treatment success was 86.6% at follow-up. 
Conclusion: The s/T ratio is effective to determine symptom dominance in men with LUTS and can guide medical treatment selection 
through better identification of symptoms. 
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2. Materials and methods
2.1. Patient selection
A total of 54 men (>45 years of age) with moderate or severe 
LUTS on the IPSS were prospectively included in this study. 
Exclusion criteria were the diagnoses of any lower urinary 
tract condition other than prostatic enlargement (prostate 
cancer, surgery, infection, stones, strictures, neurological 
diseases, etc.), previous prostatic surgery, and medication 
for BOO and/or DO. The institutional review board and 
ethics committee approved the study protocol. Prostate-
specific antigen (PSA), IPSS, uroflowmetry, prostate 
volume, postvoiding residual urine volume (PVR), and 
pressure flow study (PFS) were measured in all patients. 
All patients were further divided into 2 groups 
according to the s/T ratio obtained by dividing the total 
score of all questions examining storage function in the 
IPSS (2nd, 4th, and 7th) by the total score of all questions 
(15/35 = 0.43). Patients were grouped by s/T cut-off value of 
0.43 (Group 1 at <0.43 and Group 2 at >0.43). Tamsulosin 
(0.4 mg, once daily per os) was administered in Group 1, 
while tolterodine ER (TER; 4 mg, once daily per os) was 
administered in Group 2. Patients were evaluated during 
the 1st and 3rd months of follow-up treatment. Treatment 
success was defined as symptom improvement by IPSS of 
≥4 points on 2 consecutive visits, 1 point improvement of 
QoL score, and/or any rise of maximum flow rate (Qmax) 
(12,13). A treatment algorithm according to the design of 
the study is shown in Figure 1. ComRx was administered 
in case of treatment failure during the 1st month of follow-
up treatment. Treatment success of ComRx was evaluated 
1 month after starting the ComRx treatment as stated 
above. If a patient’s Qmax was <8 mL/s and PVR was >200 
mL after initial treatment, transurethral resection of the 
prostate (TURP) was performed and these patients were 
excluded from the study. 
2.2. Pressure flow studies 
All patients underwent PFS, and the bladder outlet 
obstruction index (BOOI) and bladder contractility index 
(BCI) were calculated using the following formulas:
BOOI: detrusor pressure at maximum flow rate 
(PdetQmax) – 2 × maximum flow rate (Qmax).
BCI: PdetQmax + 5 × Qmax.
Patients were categorized into 3 groups with reference 
to the BOOI score: obstructed (BOOI of >20), equivocal 
(BOOI = 20–40), or unobstructed (BOOI of <20). Using 
BCI, patients were categorized into groups with strong 
(BCI of >100), normal (BCI = 100–150), and weak (BCI 
of <100) contractility. 
2.3. Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPSS 
Inc., Chicago, IL, USA). The Mann–Whitney U test and 
chi-squared test were used to compare the 2 groups. The 
Wilcoxon rank test and logistic regression analysis were 
performed to determine treatment success. P < 0.05 was 
accepted as statistically significant.
3. Results
The mean age of the patients was 62.1 ± 8 years. There were 
37 (68.5%) patients in Group 1 and 17 (31.5%) in Group 
2. The mean s/T ratios of Groups 1 and 2 were 0.33 ± 0.08 
and 0.59 ± 0.1, respectively. No statistically significant 
difference was found in the pretreatment variables between 
the groups for the s/T ratios (Table 1). Five (13.5%) patients 
in Group 1 and 8 (47%) in Group 2 had statistically 
significant differences in urge urinary incontinence (P 
= 0.01). When we compared the pretreatment variables 
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Figure 1. Treatment algorithm according to design of the study. 
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between the 2 groups, only the maximum cystometric 
capacity was higher in Group 1 (P < 0.001) (Table 1). 
Treatment success of Groups 1 and 2 was 88.4% and 
75.7%, respectively. The data from the baseline and the 1st 
and 3rd months’ follow-up variables in Groups 1 and 2 are 
shown in Figures 2 and 3, respectively. The mean s/T ratios 
in Groups 1 and 2 changed from 0.33 ± 0.08 to 0.38 ± 0.19 
(P = 0.03) and from 0.59 ± 0.1 to 0.54 ± 0.18 (P = 0.17) in 
the 3rd month of follow-up treatment, respectively. When 
we compared the data from each group in terms of total 
IPSS, storage and voiding scores, QoL score, and Qmax 
(mL/s) in the follow-up periods, all parameters were 
statistically different from baseline values, except for Qmax 
in the 1st month of follow-up for Group 2 (Figures 2 and 
3). Significant decreases were found in total IPSS (–7.6), 
along with an improvement in QoL score (–1.6), a slightly 
Table 1. Comparison of patient pretreatment variables according to s/T ratio.
Group 1








Age 61 ± 7.59 60.9 ± 8.8 0.96
Total IPSS 17.8 ± 5.84 16.2 ± 8.14 0.44
QoL score 3.52 ± 1.1 3.53 ± 1.3 0.92
Total PSA (ng/mL) 1.5 ± 1.06 1.62 ± 1.33 0.744
Prostate volume (cm3) 32.9 ± 16.5 32 ± 15.5 0.859
Maximum cystometric capacity (mL) 381.14 ± 77.4 262.8 ± 143.3 0.006
Qmax (mL/s) 11.9 ± 3.77 15.1 ± 6.18 0.08
Maximum detrusor pressure during voiding phase 69 ± 27.4 62.7 ± 16 0.47
Maximum detrusor pressure during maximum flow 50.9 ± 25 46.8 ± 12.1 0.6
Voiding volume (mL) 282 ± 135.8 276 ± 141.8 0.891
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Figure 2. Mean values of IPSS, storage and voiding subscale 
scores, QoL, and Qmax (mL/s) in Group 1 during the follow-up 
period. 
*: Statistically significant difference was found when comparing 
1st month follow-up values with baseline values.
†: Statistically significant difference was found when comparing 
3rd month follow-up values with baseline values.
Figure 3. Mean values of IPSS, storage and voiding subscale 
scores, QoL, and Qmax (mL/s) in Group 2 during the follow-up 
period.
*: Statistically significant difference was found when comparing 
1st month follow-up values with baseline values.
†: Statistically significant difference was found when comparing 
3rd month follow-up values with baseline values.
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increased Qmax ( +1.33 mL/s), and a minimally decreased 
PVR (–22.6 mL) in Group 2 during the 3rd month of 
follow-up. The PVR of unsuccessful cases in the 1st month 
of follow-up treatment (95 ± 65 mL) was significantly 
higher than in the successful counterparts (42 ± 36.2 mL) 
in Group 1 (P = 0.007). The multivariate analysis showed 
that only PVR was identified as an independent predictive 
factor affecting treatment success in Group 1 (P = 0.004; 
odds ratio = 1.05, range: 1.01–1.07). There was no increase 
in the PVR of Group 2 during the 1st and 3rd months of 
follow-up treatment (P > 0.05). 
The calculated BOOI and BCI values of Groups 1 and 
2 according to PFS are shown in Table 2. Regarding the 
baseline PFS, BOOI and BCI values of the patients did not 
show any significant difference between the groups (P = 
0.324, P = 0.153; data not shown in Table 2). 
Five patients in Group 1 and 4 patients in Group 2 did 
not respond to first-line treatments. TURP was performed 
in 2 of 5 patients in Group 1. Seven of 9 nonresponsive 
patients received ComRx and the treatment success rate 
was 86.6% (6 of 7 patients) during the 1st month of follow-
up treatment. The mean s/T ratio was 0.47 in the ComRx 
group. There was a decrease of 7.8 in IPSS and 1.88 in QoL, 
and an increase of 3.03 mL/s in Qmax with ComRx. 
The most common adverse event was mild xerostomia, 
reported by 18% of the patients (3 of 17) receiving 
antimuscarinics. No serious adverse event was reported 
to prompt drug withdrawal and no urinary retention was 
observed in either group.
4. Discussion
Epidemiological studies have shown that 60% of men 
in the general population complained about at least 1 
type of LUTS, whereas 48.4% of men with LUTS had 
only OAB symptoms and 35.2% had mixed symptoms, 
including voiding, storage, and postmicturition symptoms 
(2). Although treating the prostate gland has been an 
accepted method in LUTS management, the presence and 
predominance of OAB symptoms in bothersome LUTS 
seems to be an important issue. The determination of 
predominant symptoms of LUTS in the clinical scenario 
with noninvasive diagnostic tools is challenging. 
α-Blockers are widely accepted as the first-line treatment 
for men with LUTS suggestive of BOO. Although there 
are controversies concerning treatment success criteria 
of α-blockers in the literature, studies have reported that 
56%–80% of patients had improved symptoms using 
α-blockers (12,14). In the present study, treatment success 
with tamsulosin monotherapy was 88.4%, which was 
higher than in previous studies. We think that our success 
rate was related to the selection of appropriate patients 
who would likely benefit from tamsulosin monotherapy. 
Additionally, a significant increase in the mean s/T ratio 
(0.33 to 0.38) indicated that tamsulosin improved voiding 
symptoms rather than storage symptoms. 
Although antimuscarinics reduce DO and are 
indicated for the treatment of OAB, until recently, many 
men have been only prescribed antimuscarinics for 
persistent OAB symptoms following prostatic surgery 
(8). Antimuscarinic therapy in men with LUTS has 
traditionally been avoided due to an increased risk of 
acute urinary retention in BOO cases. However, primary 
studies (15,16) and post hoc analyses (17,18) suggested 
that antimuscarinics were not associated with an increased 
incidence of urinary retention and substantial increase 
of PVR in men with OAB with or without other LUTS. 
Kaplan et al. (16) evaluated the effectiveness of TER 
monotherapy in men with LUTS who did not respond to 
initial α-blocker treatment and found significant changes 
in total IPSS (–6.1), peak urinary flow rate ( +1.9 mL/s), 
and PVR (–22 mL) after 6 months of TER monotherapy. 
They also reported that the storage and voiding scores 
Table 2. Comparisons of the BOO and BC indexes of patients in Groups 1 and 2 according to success of the treatments 














0.05020–40 18 (24) 100–150 36 (48)






0.24720–40 9 (27.2) 100–150 27 (81.8)
>40 3 (9.2) >150 3 (9.1)
*: P-values indicate the comparison of each index in each group according to success of treatment.
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of patients significantly decreased after treatment and 
concluded that TER is an effective and well-tolerated 
therapy and can be used initially or after failed treatment 
with α-blockers. Similarly, we found a significant decrease 
in total IPSS (–7.6), an improvement in QoL score (–1.6), 
a slightly increased Qmax (+1.33 mL/s), and a minimally 
decreased PVR (–22.6 mL) in Group 2 during the 3rd 
month of follow-up. Additionally, the s/T ratio decreased 
from 0.59 to 0.54. Treatment success of this group was 
75.7% with TER monotherapy. Acute urinary retention 
and an increase in PVR were not detected. Hence, TER 
monotherapy seems to be safe, at least over a 12-week 
period, in patients with BOO and DO.
Recently, several groups have evaluated the efficacy 
and tolerability of ComRx in men with OAB and BOO. A 
multicenter randomized trial was conducted to investigate 
the implications of TER and tamsulosin (TIMES study) in 
men with LUTS (15), whereas others performed subgroup 
analyses using PSA, prostate size, and IPSS (6,19,20). 
Treatment success was defined as the patients’ perceptions 
of treatment benefit and was reported as 61.7% in placebo, 
65.1% in TER, 70.8% in tamsulosin, and 80% in ComRx 
therapies. The s/T ratios of their groups were 0.51, 0.5, 0.51, 
and 0.5, respectively. Improved bothersome symptoms 
with ComRx, rather than tamsulosin monotherapy, might 
be explained by the dominance of storage symptoms in 
that group. In contrast, the authors reported unsuccessful 
treatment results with TER monotherapy compared with 
a placebo, but the greater treatment success obtained in 
our study appeared to be related to the higher s/T ratio 
(0.59) in Group 2 than in the TER group of the TIMES 
study. Chapple et al. (21) evaluated the effectiveness of 
added TER to previous unsuccessful α-blocker treatment 
in men with prominent storage symptoms suggestive of 
OAB and found that additional TER caused significant 
improvements in diary variables, IPSS storage scores, and 
bothersome symptoms. The s/T ratios of the placebo and 
TER groups were 0.5 and 0.49, respectively. Regarding 
this ratio, their study group had predominant storage 
symptoms and, with respect to our hypothesis, additional 
TER treatment was successful as expected. 
A prospective randomized study evaluated the efficacy 
and safety of propiverine combined with doxazosin in 
urodynamically confirmed BOO patients with OAB 
symptoms and concluded that ComRx was more effective 
than doxazosin monotherapy (12). The calculated s/T ratio 
was 0.41 in the doxazosin group and 0.43 in the ComRx 
group; the patient groups had nearly equal voiding and 
storage symptoms according to our s/T cut-off value and 
2/3 of the patients had simultaneous BOO after urodynamic 
studies. Therefore, successful therapy was anticipated with 
doxazosin. Better results with ComRx might be explained 
by the presence of OAB symptoms. According to the s/T 
ratio, the treatment success rates in the present study were 
88.4%, 75.7%, and 86.6%, respectively, for tamsulosin, 
TER, and ComRx. In other words, we successfully treated 
84.2% of 54 patients who were admitted to our clinic with 
first-line therapy. The success rate reached 96.2% when 
the ComRx results were added. Our results indicated that 
most patients were successfully treated with any kind of 
medical therapy after the 1st month of follow-up using 
the s/T ratio. We suggest that ComRx should be initially 
prescribed in men with mixed symptoms. 
Song et al. evaluated voiding and storage functions 
with respect to bladder outlet obstruction grade and 
contractility in 232 patients treated with alfuzosin. They 
did not find any correlation between treatment success and 
the indexes (BOOI and BCI) (22). Similarly, neither the 
obstruction grade nor the contractility status in Groups 1 
and 2 impacted the treatment success in our study (P = 
0.311 and 0.466, respectively; data not shown in a table). 
These data show that urodynamic parameters do not 
predict the baseline symptom severity and improvement 
after treatment. 
The major limitation of the present study was an 
inadequate cohort number to determine a definitive s/T 
cut-off value and the lack of a placebo group. Although 
the underlying pathologies of LUTS are complex, the s/T 
ratio can predict the underlying pathology and it allows 
determination of the patients who would benefit from 
antimuscarinic administration. On the other hand, we 
suggest that different cut-off values should be defined for 
selecting first-line medical treatment including α-blockers, 
antimuscarinics, or ComRx. The other shortcoming of 
our study was the lack of using a specific validated OAB 
questionnaire in the evaluation of the patients.   
In conclusion, the s/T ratio may affect selection of 
medical treatment by better identifying storage or voiding 
symptoms and may improve success rates by preventing 
over- or underutilization of medications. We suggest 
initially administering antimuscarinic monotherapy in 
men with LUTS using the s/T ratio. However, the s/T 
cut-off value for medical treatment selection should be 
confirmed in a large prospective randomized study. 
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